Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T, Hashimoto K, Fujino K, Takahashi A, Hotta H, Maeda T, Kunishima Y, Fukuta F, Ito N, Wanifuchi A, Kato R, Okada M, Matsukawa M, Horita H, Takayanagi A, Kobayashi K, Tanaka T, Masumori N. Shindo T, et al. Among authors: takahashi a. World J Urol. 2024 May 9;42(1):307. doi: 10.1007/s00345-024-04952-z. World J Urol. 2024. PMID: 38722418
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
Okada M, Shindo T, Fujino K, Maeda T, Ito N, Takahashi A, Hotta H, Kunishima Y, Matsukawa M, Takayanagi A, Wanifuchi A, Nofuji S, Kato R, Fukuta F, Hashimoto K, Kobayashi K, Tanaka T, Masumori N. Okada M, et al. Among authors: takahashi a. Support Care Cancer. 2023 Oct 3;31(10):607. doi: 10.1007/s00520-023-08087-6. Support Care Cancer. 2023. PMID: 37787829
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group. Minami K, et al. Among authors: takahashi a. Urol Oncol. 2023 Nov;41(11):458.e9-458.e19. doi: 10.1016/j.urolonc.2023.08.008. Epub 2023 Oct 3. Urol Oncol. 2023. PMID: 37798145
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Shindo T, Hashimoto K, Takahashi A, Miyamoto S, Kunishima Y, Sato S, Fukuta F, Hiyama Y, Takayanagi A, Kato R, Wanifuchi A, Ueki Y, Okada M, Adachi H, Kobayashi KO, Tanaka T, Masumori N; Sapporo Medical University Urologic Oncology Consortium. Shindo T, et al. Among authors: takahashi a. Anticancer Res. 2024 Mar;44(3):1271-1279. doi: 10.21873/anticanres.16922. Anticancer Res. 2024. PMID: 38423657
Which characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?
Kyoda Y, Hashimoto K, Takahashi A, Maehana T, Tachikawa K, Muranaka T, Kato S, Kurisu T, Fukuta F, Kirisawa T, Okada M, Kobayashi K, Tanaka T, Hinotsu S, Masumori N. Kyoda Y, et al. Among authors: takahashi a. Curr Urol. 2024 Jun;18(2):122-127. doi: 10.1097/CU9.0000000000000194. Epub 2024 Jun 21. Curr Urol. 2024. PMID: 39176291 Free PMC article.
Annual report on National Clinical Database 2021 for gastroenterological surgery in Japan.
Ito S, Takahashi A, Ueno H, Takiguchi S, Kajiwara Y, Kakeji Y, Eguchi S, Goi T, Saiura A, Sasaki A, Takeuchi H, Tanaka C, Hashimoto M, Hiki N, Horiguchi A, Matsuda S, Mizushima T, Yamamoto H, Kitagawa Y, Shirabe K. Ito S, et al. Among authors: takahashi a. Ann Gastroenterol Surg. 2024 Oct 17;9(1):32-59. doi: 10.1002/ags3.12868. eCollection 2025 Jan. Ann Gastroenterol Surg. 2024. PMID: 39759995 Free PMC article.
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Takahashi A, Nomoto H, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, Kameda R, Kawata S, Miyoshi A, Nagai S, Miya A, Kameda H, Nakamura A, Atsumi T; MEGMI study group. Takahashi A, et al. Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39726204
4,925 results